Gilead Sciences has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been accepted by the FDA for priority review, Sanofi announced in a press release.

The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ataxia (SCA).

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vatiquinone for the treatment of children and ...

The application has been granted Priority Review and assigned a Prescription Drug User Fee Act, PDUFA, target action date of Aug. 19, 2025. “We are excited to be one step closer to bringing an ...

NEW HAVEN, Conn. - Biohaven Ltd. (NYSE: BHVN), a biotechnology company with a market capitalization of $3.87 billion, announced today that the U.S. Food and Drug Administration (FDA) has accepted its ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of ...

Southwest Rapid Rewards® Premier Credit Card review An arrow icon, indicating this redirects the user." Southwest Priority Card Overview If you've been thinking about getting a Southwest credit ...